Io Biotech Inc (IOBT)

$0.84 +0.03 (3.41%)
Market Cap 55.12M
Revenue (ttm) 0.00
Net Income (ttm) -86.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 127,000
Avg Vol 440,890
Day's Range N/A - N/A
Shares Out 65.88M
Stochastic %K 30%
Beta 0.24
Analysts Strong Sell
Price Target $9.00

Latest News on IOBT

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Jan 9, 2025, 8:05 AM EST - 10 days ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Dec 20, 2024, 8:05 AM EST - 4 weeks ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 12, 2024, 7:05 AM EST - 2 months ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 11, 2024, 4:05 PM EST - 2 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Nov 7, 2024, 10:00 AM EST - 2 months ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 3 months ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Sep 14, 2024, 2:30 AM EDT - 4 months ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 30, 2024, 4:05 PM EDT - 5 months ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 13, 2024, 7:05 AM EDT - 5 months ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

Jul 25, 2024, 4:05 PM EDT - 6 months ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

IO Biotech to Present at Jefferies Global Healthcare Conference

May 23, 2024, 8:30 AM EDT - 8 months ago

IO Biotech to Present at Jefferies Global Healthcare Conference

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 14, 2024, 7:55 AM EDT - 8 months ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 4:30 PM EDT - 9 months ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 15, 2024, 8:30 AM EDT - 9 months ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 9, 2024, 12:00 PM EDT - 10 months ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Apr 5, 2024, 8:30 AM EDT - 10 months ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 6, 2024, 4:11 PM EST - 11 months ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Mar 5, 2024, 4:40 PM EST - 11 months ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Feb 26, 2024, 4:05 PM EST - 11 months ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

IO Biotech: A Phase 3 Company Getting No Respect

Jan 3, 2024, 3:04 AM EST - 1 year ago

IO Biotech: A Phase 3 Company Getting No Respect

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Dec 21, 2023, 8:30 AM EST - 1 year ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:12 AM EST - 1 year ago

IO Biotech Announces 2023 Third Quarter Results

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 13, 2023, 8:00 AM EST - 1 year ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 10, 2023, 8:00 AM EST - 1 year ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 1, 2023, 8:30 AM EDT - 1 year ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 23, 2023, 1:00 AM EDT - 1 year ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 3, 2023, 4:30 PM EDT - 1 year ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Sep 12, 2023, 8:05 AM EDT - 1 year ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

IO Biotech Announces 2023 Second Quarter Results

Aug 11, 2023, 8:30 AM EDT - 1 year ago

IO Biotech Announces 2023 Second Quarter Results

IO Biotech Appoints Heidi Hunter to its Board of Directors

Aug 11, 2023, 8:05 AM EDT - 1 year ago

IO Biotech Appoints Heidi Hunter to its Board of Directors

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

Aug 8, 2023, 8:05 AM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

IO Biotech, Inc. Announces $75 Million Private Placement Financing

Aug 7, 2023, 8:30 AM EDT - 1 year ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

Jul 28, 2023, 8:05 AM EDT - 1 year ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

Jul 25, 2023, 4:05 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

Jul 18, 2023, 4:05 PM EDT - 1 year ago

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

Jun 14, 2023, 8:00 AM EDT - 1 year ago

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

Jun 1, 2023, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

IO Biotech to Present at the Jefferies Healthcare Conference

May 30, 2023, 4:35 PM EDT - 1 year ago

IO Biotech to Present at the Jefferies Healthcare Conference

IO Biotech Announces 2023 First-Quarter Results

May 11, 2023, 4:05 PM EDT - 1 year ago

IO Biotech Announces 2023 First-Quarter Results

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

Mar 14, 2023, 4:11 PM EDT - 2 years ago

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

IO Biotech to Participate in March 2023 Investor Conferences

Feb 22, 2023, 7:00 AM EST - 2 years ago

IO Biotech to Participate in March 2023 Investor Conferences

IO Biotech Announces Appointment of Devin Smith as General Counsel

Jan 23, 2023, 8:00 AM EST - 2 years ago

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Provides Business Update

Jan 9, 2023, 7:05 AM EST - 2 years ago

IO Biotech Provides Business Update

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 9, 2022, 4:07 PM EST - 2 years ago

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

IO Biotech Announces Third Quarter Results for 2022

Nov 9, 2022, 4:05 PM EST - 2 years ago

IO Biotech Announces Third Quarter Results for 2022

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

Nov 3, 2022, 8:00 AM EDT - 2 years ago

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

IO Biotech to Participate in the Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 2 years ago

IO Biotech to Participate in the Jefferies London Healthcare Conference

IO Biotech Announces Appointment of New Chief Financial Officer

Oct 13, 2022, 4:05 PM EDT - 2 years ago

IO Biotech Announces Appointment of New Chief Financial Officer

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 5, 2022, 8:05 AM EDT - 2 years ago

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Sep 6, 2022, 7:30 AM EDT - 2 years ago

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference